U.S., July 15 -- ClinicalTrials.gov registry received information related to the study (NCT07061938) titled 'Study to Assess Safety, Efficacy and Persistence of ACE1831, in Subjects With IgG4-Related Disease' on May 27.
Brief Summary: ACE1831 is an off-the-shelf, allogeneic gamma delta T (gdT) cell therapy derived from healthy donors, that is under investigation for the treatment in subjects with Immunoglobulin G4 Related Disease (IgG4-RD)
Study Start Date: Aug. 01
Study Type: INTERVENTIONAL
Condition:
IgG4 Related Disease
Intervention:
DRUG: ACE1831
ACE1831 is allogeneic gamma delta T (gdT) cell therapy. Subjects will receive ACE1831 dose based on the assigned dose escalation cohort.
DRUG: Lymphodepleting chemotherapy
Subjects as...